DavidNagelMDPhD(He/Him)
Pulmonology • Rochester, NYCritical Care Medicine, Interstitial Lung Diseases
Assistant Professor
Dr. Nagel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
601 Elmwood Ave
Department of Pulmonary and Critical Care Medicine
Rochester, NY 14642Phone+1 585-275-4161Fax+1 585-273-1171
Summary
- David Nagel, MD is a Pulmonologist located in Rochester, NY with subspecialties in Critical Care Medicine and Interstitial Lung Diseases. He completed his residency and chief residency in Internal Medicine at Dartmouth-Hitchcock/Mary Hitchcock Memorial Hospital, graduating in 2011. He then completed a Fellowship in Pulmonary Disease and Critical Care Medicine at the University of Rochester from 2015 to 2018. Dr. Nagel currently works at the University of Rochester Medical Center. His expertise lies in treating conditions such as respiratory failure, interstitial lung disease, sarcoidosis, idiopathic pulmonary fibrosis, and critical care medicine. He has several reputable publications in his field and has participated in clinical trials focusing on treatments for Idiopathic Pulmonary Fibrosis.
Education & Training
University of RochesterFellowship, Pulmonary Disease and Critical Care Medicine, 2015 - 2018
Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalChief Residency, Internal Medicine, 2014 - 2015- Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalResidency, Internal Medicine, 2011 - 2014
University of Rochester School of Medicine and DentistryClass of 2011
Certifications & Licensure
NH State Medical License 2014 - Present
NY State Medical License 2016 - 2025
VT State Medical License 2014 - 2016- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
Clinical Trials
- Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial Start of enrollment: 2020 Dec 17
- Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis Start of enrollment: 2021 Jun 01
- Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2024 Jan 31
Publications & Presentations
PubMed
- 6 citationsAssociation between weight loss and mortality in idiopathic pulmonary fibrosis.Aleksandr Kalininskiy, Ashley Rose Rackow, David Nagel, Daniel Croft, Heather McGrane-Minton
Respiratory Research. 2022-12-24 - 3 citationsThe Novel Small Molecule BTB Inhibits Pro-Fibrotic Fibroblast Behavior though Inhibition of RhoA Activity.Ashley R Rackow, David J Nagel, Gregory Zapas, Ryan S Clough, Patricia J Sime
International Journal of Molecular Sciences. 2022-10-08 - 4 citationsCell-Type-Specific Effects of the Ovarian Cancer G-Protein Coupled Receptor (OGR1) on Inflammation and Fibrosis; Potential Implications for Idiopathic Pulmonary Fibrosis.David J Nagel, Ashley R Rackow, Wei-Yao Ku, Tyler J Bell, Patricia J Sime
Cells. 2022-08-16
Press Mentions
How Fixes for N.H.'s Opioid Crisis May Be Hurting Those with Chronic PainSeptember 20th, 2017
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
